---
title: "BioCardia (BCDA) news: offering"
url: "https://aibio.space/companies/biocardia/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "BCDA offering news: BioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales. BioCardia, Inc."
---

BCDA BioCardia, Inc. NASDAQ · United States

# BioCardia (BCDA) news BCDA offering news

Listings · 2026-06-12

## [BioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales](https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance-2/)

Nasdaq granted BioCardia until October 7, 2026 to regain compliance. The company says at-the-market sales with H.C. Wainwright & Co. brought net proceeds of $4.9 million and that it believes equity now exceeds $2.5 million.

## Latest BioCardia news

1. 2025-10-02 Listings [BioCardia regains compliance with Nasdaq equity rule](https://aibio.space/news/biocardia-regains-compliance-nasdaq-equity-rule/) Nasdaq staff told BioCardia in writing that it again meets the Equity Rule, but the 8-K gives no equity figure and does not say how the gap was closed.
2. 2025-09-24 Listings [BioCardia believes it regained Nasdaq stockholders' equity compliance after stock sales](https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance/) BioCardia says its stockholders' equity exceeds the $2.5 million Nasdaq minimum after two private placements, an offering with net proceeds of about $5.1 million and at-the-market sales. Nasdaq will keep monitoring the company.
3. 2025-09-16 Financings [BioCardia files for best-efforts stock and warrant offering, later prices it at $1.25](https://aibio.space/news/biocardia-files-best-efforts-stock-warrant-offering-later-prices-1-25/) The September 16 registration covered up to 2,800,000 shares at an assumed $2.27. On September 18 the final prospectus sold 4,800,000 shares with warrants at $1.25, for $6,000,000.

## BioCardia at a glance

- **Ticker**: BCDA

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $4.1 million

### Related companies

- [Nurix Therapeutics](https://aibio.space/companies/nurix-therapeutics/) NASDAQ: NRIX
- [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) NASDAQ: FLNA
- [Monopar Therapeutics](https://aibio.space/companies/monopar-therapeutics/) NASDAQ: MNPR
- [Pliant Therapeutics](https://aibio.space/companies/pliant-therapeutics/) NASDAQ: PLRX
- [Dianthus Therapeutics](https://aibio.space/companies/dianthus-therapeutics/) NASDAQ: DNTH
- [Lakewood-Amedex Biotherapeutics](https://aibio.space/companies/lakewood-amedex-biotherapeutics/) NASDAQ: LABT
- [Cel-Sci](https://aibio.space/companies/cel-sci/) AMEX: CVM
- [Precision BioSciences](https://aibio.space/companies/precision-biosciences/) NASDAQ: DTIL

### Also on NASDAQ

- [Intercure](https://aibio.space/companies/intercure/) INCR
- [Turn Therapeutics](https://aibio.space/companies/turn-therapeutics/) TTRX
- [Eloxx Pharmaceuticals](https://aibio.space/companies/eloxx-pharmaceuticals/) ELOX
- [Adaptive Biotechnologies](https://aibio.space/companies/adaptive-biotechnologies/) ADPT
- [Aligos Therapeutics](https://aibio.space/companies/aligos-therapeutics/) ALGS
- [Quantum Cyber](https://aibio.space/companies/quantum-cyber-n-v/) QUCY

## BioCardia annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$5.0 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/) | [$4.4 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/) |
| Net income (loss) | [-$8.2 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/) | [-$7.9 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/) |
| Cash from operations | [-$7.4 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/) | [-$7.9 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/) |
| Cash and equivalents | [$2.5 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926027315/) | [$2.4 million](https://www.sec.gov/Archives/edgar/data/925741/000143774926009587/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.1 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about BioCardia

Has BioCardia raised money recently?

Our latest story on this, dated Jun 12, 2026: "BioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance-2/).

What is the ticker symbol of BioCardia?

BioCardia, Inc. trades under the ticker BCDA on NASDAQ.

Where is BioCardia listed?

BioCardia, Inc. is listed on NASDAQ.

What is the SEC CIK of BioCardia?

The SEC Central Index Key (CIK) for BioCardia, Inc. is 925741. Its filings are on SEC EDGAR.

How many shares does BioCardia have outstanding?

15,138,782 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-12.

Which country or territory is BioCardia listed under?

Our directory records BioCardia, Inc. under United States.

What does BioCardia do?

Our directory classifies BioCardia, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of BioCardia?

The ISIN recorded for BioCardia, Inc. is US09060U6064.

Does aibio.space cover BioCardia?

aibio.space lists BioCardia, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is BioCardia incorporated?

SEC records list its state or country of incorporation as DE.

Is BioCardia profitable?

BioCardia, Inc. reported a net loss of $8.2 million for the fiscal year ended Dec 31, 2025, and used $7.4 million of cash in operations, per its annual report to the SEC.

How much does BioCardia spend on research and development?

$5.0 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does BioCardia have?

$4.1 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest BioCardia (BCDA) stock news?

Our latest story on BioCardia, dated Jun 12, 2026: "BioCardia believes it regained Nasdaq stockholders' equity compliance after at-the-market sales". Nasdaq granted BioCardia until October 7, 2026 to regain compliance. The company says at-the-market sales with H.C. Wainwright & Co. brought net proceeds of $4.9 million and that it believes equity now exceeds $2.5 million. [Source](https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance-2/).

How long will BioCardia's cash last?

From our story of Jun 12, 2026: The company lists its ability to raise funding, to continue as a going concern and to keep its Nasdaq Capital Market listing among its stated expectations. [Source](https://aibio.space/news/biocardia-believes-regained-nasdaq-stockholders-equity-compliance-2/).

## Investor discussion: BioCardia

Members talk about BioCardia (BCDA). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at BioCardia, newest first. Each line links the filing it comes from.

1. 2026-09-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774926030831/bcda20260921_8k.htm)
2. 2026-08-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774926028744/bcda20260819_8k.htm)
3. 2026-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774926020384/bcda20260612_8k.htm)
4. 2026-06-08 Financings Reported a financing. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774926019789/bcda20260607_8k.htm)
5. 2026-04-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774926012412/bcda20260414_8k.htm)
6. 2025-10-24 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774925031727/bcda20251024_424b5.htm)
7. 2025-10-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774925030217/bcda20251001_8k.htm)
8. 2025-09-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774925029768/bcda20250923_8k.htm)
9. 2025-09-16 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774925029116/bcda20250801_s1.htm)
10. 2025-04-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774925011030/bcda20250401_8k.htm)
11. 2024-12-02 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/925741/000143774924036481/bcda20241202_424b5.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:BCDA on TradingView](https://www.tradingview.com/symbols/NASDAQ-BCDA/).

## SEC filings and registration

- **SEC name**: BioCardia, Inc.

- **CIK**: 925741

- **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836)

- **US tickers**: BCDA (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: Non-accelerated filer<br>Smaller reporting company

- **Business address**: 320 SOQUEL WAY, SUNNYVALE, CA, 94085

- **Phone**: 650-226-0123

- **Shares outstanding**: 15,138,782 as of 2026-08-11 (10-Q filed 2026-08-12)

- **Former names**: Tiger X Medical, Inc.; Cardo Medical, Inc.; CLICKNSETTLE COM INC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926032887/bcda20261018_8k.htm) filed 2026-10-19
- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926032270/bcda20261007_8k.htm) filed 2026-10-07
- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926031665/bcda20261001_8k.htm) filed 2026-10-01
- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926031011/bcda20260923_8k.htm) filed 2026-09-23
- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926030831/bcda20260921_8k.htm) filed 2026-09-21
- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926030023/bcda20260908_8k.htm) filed 2026-09-10
- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926028778/bcda20260821_8k.htm) filed 2026-08-24
- [8-K](https://www.sec.gov/Archives/edgar/data/925741/000143774926028744/bcda20260819_8k.htm) filed 2026-08-21

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000925741), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

BioCardia, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker BCDA, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: BioCardia, Inc.

- **Ticker**: BCDA

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US09060U6064

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-BCDA/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/biocardia/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "BioCardia (BCDA) news: offering", 2026-10-31, https://aibio.space/companies/biocardia/